

- Meningitis**
 approach to the patient, 883–884, 884–885f
 bacterial, **885**
 A. baumannii, 1037
 clinical features of, 783, 887, 998–999
 complications of, 952
 deaths from, 890
 definition of, 885
 diagnosis of, **887**
 blood culture, 887, 951
 CSF analysis, 764, 766t, 888t, 951
 signs and symptoms, 998–999
 differential diagnosis of, 888, 951
 E. coli, 1028
 enterococcal, 974, 975t
 epidemiology of, 885
 etiology of, 780t, 783, 885–886
 gram-negative, 889t, 890
 H. influenzae, 886, 1011
 incidence of, 885
 increased ICP in, 890
 in infants, 970
 L. monocytogenes, 886, 889–890, 889t, 983
 meningococcal, 780t, 885, 889, 889t, 998–999
 nontyphoidal *Salmonella*, 1054, 1054t
 pathophysiology of, 886–887, 886f
 plague, 1072
 pneumococcal, 780t, 885, 889, 889t, 951
 prognosis of, 890
 prophylaxis for exposure to, 945t
 risk factors for, 783
 staphylococcal, 886, 889t, 890
 streptococcal, 970
 T. pallidum, 1135
 treatment of
 adjunctive, 890
 algorithm for, 884–885f
 antimicrobial therapy based on pathogen, 889–890, 889t, 975t, 1011
 empirical antimicrobial therapy, 767t, 780t, 887t, 889, 1000
 ICP-related, 890
 in cancer patient, 488, 1792–1793
 chronic, **906**
 amebic, 1367–1368
 approach to the patient, 907, 909
 bacterial, 907–908t
 basal, 906
 clinical features of, 906, 906t
 diagnosis of, 907–909t, 909–910, 910f
 epidemiology of, 907
 fungal, 908t
 helminthic, 908t
 in HIV infection, 907, 911
 in immunosuppressed patients, 911
 intracranial, 906
 Mollaret's, 909t
 noninfectious causes of, 909t
 pathophysiology of, 906
 protozoal, 908t
 spinal, 906–907
 systemic manifestations of, 907
 treatment of, 910–911, 945t
 viral, 908t
Coccidioides, 441e–7f, 1336, 1337
 complications of, 974
Cryptococcus, 1264, 1340, 1341
 delirium in, 169
 fungal, 898
 global considerations in, 898
 headache in, 108
 hyponatremia in, 299
 Mollaret's, 1179
 neoplastic, 1792–1793
 in neurosyphilis, 899, 1136
 pathophysiology of, 145e–8
 in secondary syphilis, 1135
 subacute, 898–899
 tuberculous, 766t, 775, 898–899, 907t, 1111
 viral, **890**
 arbovirus, 892
 chronic, 908t
 clinical features of, 890
 diagnosis of, 764, 766t, 891
 differential diagnosis of, 892
 EBV, 892
 enteroviral, 892, 1291, 1291t
 epidemiology of, 890
 etiology of, 890, 891t, 892–893
 in HIV infection, 892–893, 1264
 HSV, 892, 908t, 1179, 1182t
 lymphocytic choriomeningitis, 891, 893, 908t, 1306t, 1317–1318
 in mumps infection, 231e–2–3, 893
 prognosis of, 893
 treatment of, 893
 VZV, 892
 weakness in, 156
Meningococcal infections, 995
 in cancer patient, 484, 484t, 486t, 488
 clinical features of, 998–999
 cutaneous, 362, 780t, 998, 999t
 meningitis. *See* Meningitis
 meningococcemia/septicemia. *See* Meningococcemia
 postmeningococcal reactive disease, 999
 postsplenectomy sepsis, 780t, 781
 complications of, 1000
 diagnosis of, 999–1000
 epidemiology of, 996–997, 996f, 997f
 etiology of. *See* *Neisseria* spp. (meningococci); *Neisseria meningitidis*
 genetic considerations in, 997
 global considerations in, 995–996
 pathogenesis of, 998
 prevention of. *See* Meningococcal vaccine
 prognosis of, 1000
 prophylaxis for contacts, 1002–1003
 risk factors for, 997
 treatment of, 940t, 1000
Meningococcal vaccine
 based on subcapsular antigens, 1002, 1002f
 conjugate, 1001–1002
 contraindications to, 790t
 global considerations in, 1001, 1002
 polysaccharide, 1001, 1001f
 recommended administration of
 in adults, 787–788f
 in cancer patient, 485t, 492
 in splenectomized patient, 413
 in transplant recipient, 920t, 929, 929t
 in travelers, 795, 795t
 storage and handling of, 791
Meningococcemia
 acute, 133t, 135
 chronic, 25e–11f, 133t, 135, 999
 clinical features of, 781, 999
 complications of, 781–782, 1000
 epidemiology of, 781
 etiology of, 780t, 781
 fulminant, 25e–11f, 1754, 1755
 pathogenesis of, 998
 prognosis of, 1000
 shock in, 998
 skin manifestations of
 papular lesions, 25e–11f
 petechiae, 781
 purpura, 25e–11f, 76e–9f, 133t, 342f, 369, 998
 rash, 362, 362t
 treatment of, 780t, 1000
Meningoencephalitis
Balamuthia, 1368, 1368f
Cryptococcus, 1340, 1340f
L. monocytogenes, 983
Naegleria, 1367
 Meningovascular syphilis, 1136
 Menkes' kinky hair syndrome, 96e–10
Menopause, 2381
 age at, breast cancer risk and, 524
 bone remodeling and, 2491–2492, 2492f
 cardiovascular disease risk and, 6e–3
 clinical features of, 2382, 2382f
 definition of, 2381
 hirsutism after, 332
 hormone therapy in. *See* Postmenopausal hormone therapy
 physiology of, 2381, 2381f
 premature, after cancer treatment, 103e–25, 623
 prevalence of, 2254t
 screening/testing for, 2254t, 2381–2382, 2382f
 transition to, 2382, 2382f
 Menorrhagia, 403, 730, 2382
 Men's health, **7e–1**
 anabolic-androgen steroid abuse. *See* Anabolic-androgenic steroid (AAS) abuse
 androgen deprivation therapy. *See* Androgen deprivation therapy (ADT)
 breast cancer, 523, 532
 lower urinary tract symptoms, 7e–4, 60e–1.
 See also Benign prostatic hypertrophy (BPH)
 muscle dysphoria syndrome, 7e–2
 prostate cancer. *See* Prostate cancer
 reproductive function, 7e–1–2. *See also* Erectile dysfunction (ED); Male reproductive system disorders
 testosterone and, 7e–1, 7e–1f, 7e–2f. *See also* Testosterone; Testosterone therapy
 Menstrual cycle
 duration of, 400e–6
 follicular phase of, 2378–2379, 2379f
 hormonal integration of, 400e–5, **2378**, 2378f
 luteal phase of, 2379, 2379f
Menstrual disorders, 335
 amenorrhea. *See* Amenorrhea
 definition of, 335
 diagnosis of, 335, 337f
 dysmenorrhea, 338–339
 etiology of, 335–336
 hypothalamic-pituitary-gonadal axis in, 335, 336f
 menorrhagia, 403, 730
 obesity and, 415e–6
 prevalence of, 335
 sacral pain in, 118
 treatment of, 335–336
MEN syndromes. See under Multiple endocrine neoplasia
 Mental disorders. *See* Psychiatric/psychological disorders
 Mental status assessment, 2537. *See also* Mini-Mental Status Examination (MMSE)
 Men who have sex with men (MSM)
 gonococcal infections in, 1005–1006
 HPV infection in, 1198
 intestinal infections in, 881
 sexually acquired proctitis in, 881–882
 MEONs. *See* Multiple endocrine and other organ neoplasias (MEONs)
 MEOS (microsomal ethanol oxidizing system), 2058
 Meperidine
 adverse effects of, 462e–20, 462e–20t, 2547t
 dosage in kidney disease, 37, 1821
 dosage in liver disease, 37
 overdosage/poisoning with, 473e–13t
 for pain, 91t
 Mephenytoin, 34t
 Mepolizumab, 135e–8, 422, 1686, 2187
 Meprobamate, 473e–11t
 Meralgia paresthetica (lateral femoral cutaneous neuropathy), 49, 463e–5, 463e–5f, 2692
 6-Mercaptopurine (6-MP)
 action of, 103e–14
 adverse effects of, 103e–10t, 103e–14, 417, 649, 1960, 1962
 drug interactions of, 42, 42t, 103e–10t
 genetic variations in response to, 39t, 40, 445, 1960
 for IBD, 1960
 metabolism of, 34t, 40, 42
 Mercury exposure/poisoning
 clinical features of, 472e–3t, 2608
 diagnosis of, 472e–3t
 global considerations in, 472e–3
 neuropathy due to, 2688t, 2689
 in pregnancy, 472e–1